Disease · MONDO_1060198
Comparisons in its trials124
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 124
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Acute Ischemic Stroke (AIS) Patients Aged >80 Years Who Received IV Rt-PA (Alteplase) vs Acute Ischemic Stroke (AIS) Patients Aged 18 to 80 Years Who Received IV Rt-PA (Alteplase): Number of Patients With Stroke Recurrence During Hospitalization | 369 of 3,332 | 2,039 of 28,086 | 31,418 | NCT05395351 | Trial comparisons |
| Alteplase Active Control Group vs Tenecteplase Treatment Group: deaths from any cause | 44 of 736 | 34 of 732 | 1,468 | NCT04915729 | Trial comparisons |
| Alteplase Active Control Group vs Tenecteplase Treatment Group: serious adverse events | 115 of 736 | 116 of 732 | 1,468 | NCT04915729 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL) | 15 of 581 | 0 of 570 | 1,151 | NCT01369069 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Death | 54 of 581 | 65 of 570 | 1,151 | NCT01369069 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: deaths from any cause | 54 of 581 | 65 of 570 | 1,151 | NCT01369069 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable Modified Rankin Scale (Yes/No) | 119 of 581 | 123 of 570 | 1,151 | NCT01369069 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: serious adverse events | 209 of 581 | 198 of 570 | 1,151 | NCT01369069 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Mortality Rate | 64 of 549 | 74 of 556 | 1,105 | NCT02930018 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: deaths from any cause | 64 of 549 | 74 of 556 | 1,105 | NCT02930018 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With mRS Score of 0 to 2 | 337 of 549 | 329 of 556 | 1,105 | NCT02930018 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With NIHSS Score of 0 to 2 | 320 of 549 | 320 of 556 | 1,105 | NCT02930018 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: serious adverse events | 181 of 547 | 198 of 554 | 1,101 | NCT02930018 | Trial comparisons |
| IV Insulin Drip With Target Glucose 80 mg/dL - 130 mg/dL vs Sub Q Insulin to Keep Glucose Less Than 180 mg/dL: Number of Participants With a Favorable Barthel Index | 271 of 491 | 261 of 477 | 968 | NCT01369069 | Trial comparisons |
| Nerinetide vs Placebo: Number of Participants With Good Neurological Outcome, as Defined by a Score of 0-2 on the NIHSS at Day 90 Post Randomization. | 268 of 454 | 251 of 396 | 850 | NCT04462536 | Trial comparisons |
| Nerinetide vs Placebo: Mortality Rate, as Defined by Event Rate (Percent) for Mortality Over the 90-day Study Period. | 87 of 454 | 70 of 396 | 850 | NCT04462536 | Trial comparisons |
| Nerinetide vs Placebo: Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2 | 206 of 454 | 181 of 396 | 850 | NCT04462536 | Trial comparisons |
| Nerinetide vs Placebo: deaths from any cause | 87 of 454 | 70 of 396 | 850 | NCT04462536 | Trial comparisons |
| Nerinetide vs Placebo: Number of Participants Exhibiting a Worsening of Their Index Stroke. | 76 of 454 | 68 of 396 | 850 | NCT04462536 | Trial comparisons |
| Nerinetide vs Placebo: serious adverse events | 182 of 451 | 148 of 393 | 844 | NCT04462536 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_1060198/comparisons